Search Results - "Terheyden, P"

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial by Livingstone, E., Gogas, H., Kandolf-Sekulovic, L., Meier, F., Eigentler, T.K., Ziemer, M., Terheyden, P.A.M., Gesierich, A.H., Herbst, R.A., Kähler, K.C., Ziogas, D.C., Mijuskovic, Z., Garzarolli, M., Garbe, C., Roesch, A., Ugurel, S., Gutzmer, R., Grob, J.J., Kiecker, F., Utikal, J., Windemuth-Kieselbach, C., Eckhardt, S., Zimmer, L., Schadendorf, D.

“…ImmunoCobiVem investigated whether a planned switch to atezolizumab after achieving tumour control during run-in with vemurafenib + cobimetinib improves…”
Get full text

Immune checkpoint inhibition in the era of COVID‐19 by Kurzhals, J., Terheyden, P., Langan, E. A.

Get full text

Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study by Stege, H. M., Haist, M., Schultheis, S., Fleischer, M. I., Mohr, P., Ugurel, S., Terheyden, P., Thiem, A., Kiecker, F., Leiter, U., Becker, J. C., Meissner, M., Kleeman, J., Pföhler, C., Hassel, J., Grabbe, S., Loquai, C.

“…Background Immune checkpoint inhibitors (ICI) have led to a prolongation of progression-free and overall survival in patients with metastatic Merkel cell…”
Get full text

First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab by Sadik, C.D., Thieme, M., Zillikens, D., Terheyden, P.

“…We report the case of a 42-year old woman suffering from plaque psoriasis since 1999. The psoriasis had been well controlled with the IL-17A- and…”
Get full text

Does the gastrointestinal microbiome contribute to the ‘obesity paradox’ in melanoma survival? by Langan, E.A., Grätz, V., Billmann, F., Zillikens, D., Terheyden, P.

Get full text

Complex cutaneous leishmaniasis with bone involvement by Hübner, G A, Prüßmann, W, Jossifov, N, Mischnik, A, Terheyden, P

“…We report an immunocompromised patient with a complex cutaneous leishmaniasis (CL) who suffered from singular bone involvement of the little left toe due to…”
Get more information

Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up by D'Angelo, S.P., Bhatia, S., Brohl, A.S., Hamid, O., Mehnert, J.M., Terheyden, P., Shih, K.C., Brownell, I., Lebbé, C., Lewis, K.D., Linette, G.P., Milella, M., Xiong, H., Guezel, G., Nghiem, P.T.

“…Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer that has a poor prognosis in patients with advanced disease. Avelumab [anti-programmed…”
Get full text

A prospective observational safety study of patients with BRAFV600‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study) by Corrie, P.G., Terheyden, P., Tije, A.J., Herbst, R., Jansen, R., Marples, M., Debus, D., Marconcini, R., Blasinska‐Morawiec, M., Freivogel, K., Munson, M.L.G., Goodman, G.R., Hsu, J.J., Sadetsky, N., Colburn, D., Rutkowski, P.

Get full text

A prospective observational safety study of patients with BRAF V 600 -mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study) by Corrie, P G, Terheyden, P, Ten Tije, A J, Herbst, R, Jansen, R, Marples, M, Debus, D, Marconcini, R, Blasinska-Morawiec, M, Freivogel, K, Munson, M L G, Goodman, G R, Hsu, J J, Sadetsky, N, Colburn, D, Rutkowski, P

Get full text

Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors by Terheyden, P., Weishaupt, C., Heinzerling, L., Klinkhardt, U., Krauss, J., Mohr, P., Kiecker, F., Becker, J.C., Dähling (Submitter, A., Döner, F., Heidenreich, R., Scheel, B., Schönborn-Kellenberger, O., Seibel, T., Gnad-Vogt, U.

Get full text

Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma by Shannan, B., Matschke, J., Chauvistré, H., Vogel, F., Klein, D., Meier, F., Westphal, D., Bruns, J., Rauschenberg, R., Utikal, J., Forschner, A., Berking, C., Terheyden, P., Dabrowski, E., Gutzmer, R., Rafei-Shamsabadi, D., Meiss, F., Heinzerling, L., Zimmer, L., Livingstone, Elisabeth, Váraljai, Renáta, Hoewner, A., Horn, S., Klode, J., Stuschke, M., Scheffler, B., Marchetto, A., Sannino, G., Grünewald, T.G.P., Schadendorf, D., Jendrossek, V., Roesch, A.

“…Treatment of patients with metastatic melanoma is hampered by drug-resistance and often requires combination with radiotherapy as last-resort option. However,…”
Get full text

3323 The GERMELATOX DeCOG-trial: The attitude of German melanoma patients towards toxicity during adjuvant interferon treatment - Differences between the patient's and the physician's perspective by Kaehler, K.C, Augustin, M, Blohme, C, Forschner, A, Gutzmer, R, Garbe, C, Heinzerling, L, Kornek, T, Livingstone, E, Loquai, C, Maul, L.V, Rudolph, B, Schadendorf, D, Stade, B, Terheyden, P, Gebhardt, C, Wagner, T, Hauschild, A

Get full text

3338 Initial safety results from a multinational, prospective, observational study in advanced melanoma (MEL) (IMAGE) by Middleton, M, Dalle, S, Corrie, P, Loquai, C, Terheyden, P, Kähler, K.C, Meiss, F, Board, R, Arance, A.M, Gutzmer, R, Tarhini, A, Dummer, R, Ernst, S, Richtig, E, Wolter, P, Bulger, K, Kotapati, S, Le, T.K, Brokaw, J, Abernethy, A.P

Get full text

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2 by BECKER, J. C, TERHEYDEN, P, KÄMPGEN, E, WAGNER, S, NEUMANN, C, SCHADENDORF, D, STEINMANN, A, WITTENBERG, G, LIEB, W, BRÖCKER, E.-B

“…Malignant melanoma of the uvea is remarkable for purely haematogenous dissemination and its tendency to metastasise to the liver. Although the liver is…”
Get full text

Immune checkpoint inhibition in Merkel cell carcinoma by Terheyden, P, Mohr, A, Langan, E A

“…Merkel cell carcinoma (MCC) is a rare but aggressive form of skin cancer in which Merkel cell polyomavirus infection and chronic exposure to ultraviolet…”
Get full text

Cutaneous angiosarcoma : Radiochemotherapy with liposomal pegylated doxorubicin by Bönisch, N, Langan, E A, Terheyden, P

“…Whilst cutaneous angiosarcoma is rare tumour which primarily affects elderly patients, its management presents a significant therapeutic challenge. Indeed,…”
Get full text

Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group by TERHEYDEN, P, KORTÜM, A. K, BECKER, J. C, BRÖCKER, E. B, SCHULZE, H. J, DURANI, B, REMLING, R, MAUCH, C, JUNGHANS, V, SCHADENDORF, D, BEITEKE, U, JÜNGER, M

“…To scrutinize published data from small mono-centric studies and case reports which implicated high response rates and promising survival times for a…”
Get full text

Development of serous retinopathy during therapy of a metastatic cutaneous melanoma by Lüdeke, I, Terheyden, P, Grisanti, S, Lüke, M

“…Inhibitors of the mitogen-activated protein kinase (MAPK) signal pathway have decisively improved the prognosis of metastatic cutaneous melanoma in patients…”
Get full text

Spectroscopic imaging of the human liver using 3D CSI: optimization and application in patients with metastatic uvea melanoma by Beer, M, Winkelmann, V, Becker, J C, Terheyden, P, Stenzel, M, Bröcker, E-B, Hahn, D, Köstler, H

“…(31)P MR spectroscopy (MRS) allows the noninvasive assessment of metabolic alterations in tumors. Due to physical as well as technical limitations, mostly…”
Get more information

Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma by TERHEYDEN, P, BRÖCKER, E.-B, BECKER, J. C

“…Results from in vitro chemosensitivity testing recommend treosulfan/gemcitabine chemotherapy for the treatment of stage IV uveal melanoma. Twenty patients…”
Get full text